Clarity in cell line development

Mark Stockdale joins Solentim in new “Amalgamator of Business and Biology” position

Bournemouth, UK, 8th October 2019: Solentim, the global leader in cell line development instrumentation, is delighted to announce that Mark Stockdale is starting at Solentim in a brand-new role as Amalgamator of Business and Biology. Mark has previously spent 10 years at Horizon Discovery, most recently working within the Applied Products Division as an R&D …

Read more Mark Stockdale joins Solentim in new “Amalgamator of Business and Biology” position

Dr Mark Truesdale joins Solentim as new Chief Marketing Officer

Solentim, the global leader in cell line development (CLD) instrumentation, is delighted to announce that Dr Mark Truesdale will join the Company as the new Chief Marketing Officer, effective immediately. Mark brings with him a wealth of experience, most recently seven years at Thermo Fisher Scientific, during which time he held the position of Senior …

Read more Dr Mark Truesdale joins Solentim as new Chief Marketing Officer

Solentim reports continued strong growth in 2019

NEWS – Bournemouth, UK – 8th August 2019: Solentim, the innovator and World leader in Cell Line Development instrumentation, is pleased to announce that it achieved very strong revenue growth and financial results for the first half of 2019. Commenting on the performance, Dr Ian Taylor, Chief Commercial Officer noted “Our results are in line with …

Read more Solentim reports continued strong growth in 2019

Solentim and SAL Scientific announce partnership for novel growth supplements in cell line development

Solentim, the global leader in cell line development (CLD) imaging instrumentation, and SAL Scientific, a leading provider of growth enhancing animal-free cell culture reagents, are pleased to announce a new strategic partnership. The collaboration will further optimise CLD workflow by supplying novel supplements which substantially improve cell growth. Solentim will act as the exclusive distributor for …

Read more Solentim and SAL Scientific announce partnership for novel growth supplements in cell line development

Valitacell and Solentim secure €3.5m funding to optimise the development of new biologics and cell therapies

A consortium, consisting of Valitacell, Solentim and Microcoat, has been awarded €2.5million under the highly competitive H2020 Fast Track to Innovation (FTI) initiative, and a further €1million from other sources Solentim and Valitacell announce a total of €3.5m funding to produce an integrated platform to deposit, culture, profile and select optimal cells for the manufacture of life-saving …

Read more Valitacell and Solentim secure €3.5m funding to optimise the development of new biologics and cell therapies